Articles

A Nurse Navigator’s Perspective on CDK4/6 Inhibitors

A Payer’s Perspective on CDK4/6 Inhibitors

Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Perspectives

A Pharmacist’s Perspective on CDK4/6 Inhibitors

Original Research

Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines

Bruce S. Pyenson, FSA, MAAA; Gabriela Dieguez, FSA, MAAA; Christine Ferro; Maushumi Mavinkurve, MPH; Yuri Sanchez Gonzalez, PhD

Stakeholder Perspective

Importance of Health Outcomes Research for the Treatment of Hepatitis C Infection

Jack E. Fincham, PhD, RPh

Original Research, Practice Management

Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States

Eric M. Maiese, MHS, PhD; Kristin A. Evans, PhD; Bong-Chul Chu, PhD; Debra E. Irwin, MSPH, PhD

Stakeholder Perspective

Improved Clinical Outcomes with Newer Multiple Myeloma Therapies Associated with Increased Resource Utilization and Financial Burden

Matthew Mitchell, PharmD, MBA, FAMCP

Perspectives

Still at It

David B. Nash, MD, MBA

Original Research

Predictors of Transitioning to Incident Chronic Opioid Therapy Among Working-Age Adults in the United States

J. Douglas Thornton, PharmD, PhD; Nilanjana Dwibedi, PhD; Virginia Scott, PhD; Charles D. Ponte, PharmD; Douglas Ziedonis, MD; Nethra Sambamoorthi, PhD; Usha Sambamoorthi, PhD

Stakeholder Perspective

Addiction Prediction: Preventing Iatrogenic Opioid Dependence

Albert Tzeel, MD, MHSA, CPE, FAAPL

Press Releases, Original Research

Researchers Identify 4 Predictors of Transition to Chronic Opioid Use Based on Readily Available Opioid Regimen and Patient Factors

Practice Management

Healthcare Trends for 2018

F. Randy Vogenberg, PhD, RPh; John Santilli, MBA

Page 75 of 244
Results 741 - 750 of 2434

Articles

Subscribe Today!

I'd like to receive: